In addition, FOXA1 expression is associated with luminal A subtype of BC [46] and its overexpression mediates endocrine resistance in metastatic BC by inducing the redistribution of ERα binding sites, which alter the expression of ERα target genes [48]. This evidence concerns the gene FOXA1 and breast cancer.